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Abstract
Objective
People aging with HIV might have different health conditions compared with people who se-
roconverted at older ages. The study objective was to assess the prevalence of, and risk
factors for, individual co-morbidities and multimorbidity (MM) between HIV-positive patients
with a longer duration of HIV infection, and patients who seroconverted at an older age. We
compared estimates across both groups to a matched community-based cohort sampled
from the general population.
Methods
We performed a case-control study including antiretroviral therapy (ART)–experienced pa-
tients who were HIV seropositive for 20.6 years (“HIV-Aging”), or who were seropositive
for < 11.3 years (“HIV-Aged”) having access in 2013 at the Modena HIV Metabolic Clinic.
Patients were matched in a 1:3 ratio with controls from the CINECA ARNO database. MM
was defined as the concurrent presence of >2 NICM. Logistic regression models were con-
structed to evaluate associated predictors of NICM and MM.
Results
We analysed 404 HIV-Aging and 404 HIV-Aged participants in comparison to 2424 controls.
The mean age was 46.7±6.2 years, 28.9% were women. Prevalence of HIV co-morbidities
and MM were significantly higher in the HIV-positive groups compared to the general popu-
lation (p<0.001) and a trend towards higher rates of MM was found in aging vs aged group.
This difference turned to be significant in patients above the age of 45 years old (p<0.001).
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Conclusions
People aging with HIV display heterogeneous health conditions. Host factors and duration
of HIV infection are associated with increased risk of MM compared to the
general population.
INTRODUCTION
Better understanding of the intersection of HIV, aging and health is an urgent issue due to the
increasing number of people aging with HIV[1, 2] as the synergistic result of two concurrent
phenomenon: the increased life expectancy of people with HIV undergoing HAART, exten-
sively demonstrated both in high[3, 4] and middle- and low-income countries[5, 6], but also
the increasing number of people seroconverting HIV at an older age, as the result of a lower
perception of sexual risk in older people[7, 8].
For instance, in Canada the number of older adults with HIV has doubled over the past
20 years and in the Western Europe the number of people living with HIV aged 50 years and
over was estimated as almost quadrupled over the past decade[9]. Therefore the aging of HIV
epidemic is a matter of fact, with potential concern because of physical, mental and psychologi-
cal issues that can accompany both aging and HIV infection[10].
Aging with HIV is often linked to non-infectious comorbidities (NICM), including cardio-
vascular disease (CVD), hypertension, type 2 diabetes mellitus (T2DM), chronic kidney disease
(CKD), osteopenia/osteoporosis, and non-AIDS cancers. These heterogeneous comorbidities
share age and presumably HIV-infection as independent risk factors, and tend to aggregate
into complex multi-morbidity patterns (usually defined as two or more NICM being present in
the same individual concurrently)[11, 12].
Current literature focusing on HIV in older populations is concentrated among studies
comparing older HIV-positive populations with younger HIV-positive individuals, or else
comparing older HIV-positive individuals with older HIV-negative individuals[1, 13, 14]. Such
comparative studies have begun to highlight the diversity of individuals aging with HIV, in
terms of behavioural factors, social vulnerability, and ethno-racial differences, which might
contribute to differences in patterns of aging[1]. Comparative studies within groups of older
people with HIV could help us understand relationships between age and other determinants
of health, such as treatment history, diagnosis and presentation of comorbidities and, last but
not least, duration of HIV disease. Indeed, it has been suggested that people aging with long-
term HIV infection and treatment might have characteristically different health and care needs
compared with people who have seroconverted at older ages, but evidence in this area is need-
ed[1, 2].
The objective of our study was to assess and compare the prevalence of and risk factors for
individual NICM and MM among a group of HIV-positive middle-aged and older adults with
a longer duration of HIV infection, and among a group of HIV-positive middle aged and older
adults who seroconverted at an older age. We compared estimates across both groups to a
matched community-based cohort sampled from the general population.
METHODS
This study took place within the multidisciplinary Modena HIVMetabolic Clinic (MHMC) co-
hort study, which was initiated in 2004 to assess longitudinal metabolic changes among people
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attending the HIV metabolic clinic at the University of Modena and Reggio Emilia School of
Medicine. As described elsewhere[11, 15], patients undergo annual multidisciplinary assess-
ments and consultations in multiple domains, including metabolic and endocrinological mea-
sures, bone mineral density, organ function, and social factors.
Over the past 10 years an expected shift in age distribution was observed among people at-
tending the MHMC: in 2003 median age was 40 years (interquartile range 37–44) and median
age at HIV diagnosis was 33 years; in 2012 median age was 48 years (interquartile range 45–53)
and median age at HIV diagnosis was 43 years.
Participants in the MHMC cohort were eligible for inclusion in the current cross-sectional
study if their duration of HIV infection at 2013 study visit was within either the 1st or 4th quar-
tile of the cohort. Duration of HIV infection was calculated as the time between HIV diagnosis
and 2013 study visit. We then created two groups, matched on age, gender, race (all Caucasian/
white), and geographical area of origin: one group of participants who were HIV seropositive
for 20.6 years (an aging with HIV group, “HIV-Aging”), and a second group of participants
who were seropositive for< 11.3 years (an aged at HIV seroconversion group, “HIV-Aged”).
In consideration of the natural history of untreated HIV disease, and the average length of time
between seroconversion and HIV diagnosis, these two statistically driven categories were se-
lected to represent a non-overlapping cohort of participants who acquired HIV in different
time periods.
HIV-Aging and HIV-Aged participants were matched in a 1:3 ratio with participants sam-
pled from the general population in the CINECA ARNO database, on age, gender, and race
and geographical area of origin[11]. The ARNO Observatory is an on-line, multi-centre obser-
vational database in which population-based data is collected and epidemiological methods are
used to combine and aggregate large volumes of health and healthcare-related data for each in-
dividual participant[16]. These data include primary care provider-generated medication pre-
scriptions, inpatient hospital records and discharge, summaries, diagnostic laboratory tests and
radiographic examinations. This information is linked to other sources of participant data (in-
cluding vital statistics and demographics) in order to provide comprehensive tracking of clini-
cal diagnoses and healthcare use trends throughout Italy. Lifestyle/behavioural,
anthropometric and metabolic data are not collected in the CINECA ARNO database.
Outcomes
NICM diagnoses were based according the following criteria previously used in our studies
[11]. The category of CVD included the following diagnoses: myocardial infarction, coronary
artery disease, peripheral vascular disease, stroke, angina pectoris, coronary artery bypass
grafting, and angioplasty. HTN was defined as blood pressure>140/90 mmHg over two conse-
cutive measurements, T2DM as fasting serum glucose levels>126 mg/dL, and CKD as
eGFR<60 ml/min using the MDRD estimating equation. Hypertension and T2DM diagnoses
were also identified through current use of antihypertensive and hypoglycemic drugs. In the
Aging and Aged HIV-positive groups we also analysed low BMD (t-score<-2SD) using Dual-
energy X-Ray Absorptiometry.
Covariates
Demographic and health variables were characterized and compared between HIV-Aging and
HIV-Aged groups at 2013 study visit. These include age, gender, current and nadir CD4 cell
counts, plasma HIV RNA viral load, and current smoking habits, as well as anthropometric
(body mass index [BMI], waist circumference, lipodystrophy) and cardiovascular and metabol-
ic markers (triglycerides, cholesterol, fasting glucose, and HOMA).
Aging with HIV vs Later Seroconversion
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Statistical analysis
Comparisons between groups were performed using χ2 test for categorical variables with Bon-
ferroni adjusted post-hoc analyses (significant level fixed at p<0.017) and T-test or Mann-
Whitney U-test for normally and non-normally distributed continuous variables, respectively.
The probability of MM at each age was compared across HIV-Aging, HIV-Aged, and HIV-
negative groups using logistic regression models, and univariate and multivariable logistic re-
gression models were constructed to determine odds ratios (ORs) for factors associated with
MM risk.
A model was built to compare prevalence of NICM and MM in HIV-Aging and HIV-Aged
groups using the HIV-negative group as reference after correction for gender, age (in years),
and CD4 cell count<200 cell/μL. Per protocol, we assumed that, in controls, the values for
ART exposure and nadir CD4 cell count<200 cells/lL were equal to zero.
A second model, restricted to the HIV-positive groups only, examined the probability of
MM taking into account further HIV-related variables including current CD4 lymphocyte cell
count/mm3, nadir CD4 cell count, lipodystrophy phenotype, and cumulative exposure to the
antiretroviral (ARV) agent drug classes protease inhibitors (PI), nucleoside reverse transcrip-
tase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), fusion inhib-
itors (FI), or integrase inhibitors (INT). Age was expressed in years; duration of individual
ART drug class use was expressed in months; CD4 nadir<200/μL was expressed as a binary
variable.
We performed a second subanalysis restricted to elderly HIV-positive patients using the
median age as a cut off (45 years) to better estimate the role of aging with HIV, if any.
Statistical analyses were performed STATA Software package, Intercooled version 13.1 for
Mac (Stata Corp ltd, Collage Station, TX, USA).
Ethics
Approval for the Modena HIV Metabolic Clinic cohort study was obtained from the Research
Ethics Board of the University of Modena and Reggio Emilia, and all participants provided
written consent at their initial clinic visit.
RESULTS
We analyzed data from 404 HIV-Aging participants and 404 HIV-Aged participants and com-
pared them with data from 2424 control subjects. Per matching criteria, in each group mean
age was 46.7±6.2 years, and 28.9% were women.
Table 1 describes demographics and HIV characteristics of the HIV-positive groups.
Anthropometric and cardio-metabolic characteristics differed between HIV-Aging and
HIV-Aged groups. Participants in the HIV-Aging group generally exhibited a higher preva-
lence of lipoatrophy, lower BMI, and higher rates of insulin resistance than HIV-Aged
participants.
Prevalence of NICM was significantly higher in the HIV-positive groups compared to the
HIV-negative group from the general population MM was more common among both HIV-
positive groups than the HIV-negative group (p<0.001 for all comparisons; Fig 1).
Fig 2 depicts probability of MM in the three comparative groups across age distribution.
At any age the risk for MM was accentuated in HIV-Aging participants compared to HIV-
negative individuals, and HIV-Aged participants had an intermediate risk between the
other two.
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In multivariable models including age, gender, and nadir CD4 count, we observed 5-fold in-
creased odds of MM in HIV-Aging participants compared to HIV-negative individuals
(OR = 5.0, 95% CI,3.3–7.6, p<0.01), and 4-fold increased odds of MM in HIV-Aged partici-
pants compared to HIV-negative (OR = 3.8, 95% CI,2.5–6.0, p<0.01) (Fig 3).
Comparing Aging and Aged group, the former had higher rates of hypertension (36.0 vs
26.0, p = 0.001) and a trend towards less prevalence in MM was sown in the latter (10.9 vs 8.7,
p = 0.286) (Fig 1).
In the subset of HIV patients over-45 years old, including 502 individuals, prevalence of
MM in HIV-Aged vs. HIV-Aging was 42% and 58%, (p = 0.181). In multivariable logistic re-
gression we documented a statistically significant increased risk of MMin HIV-Aging com-
pared to HIV-Aged patients (OR 1.92, 95% C.I. 1.03–3.56, p = 0.039) after adjustment for
gender (OR 3.46, 95% C.I. 1.19–10.04, p = 0.023), age (per 1 yr increase OR 1.08, 95% C.I.
1.02–1.14, p = 0.004), lipodystrophy, and cumulative exposure to ARVs (Fig 4).
DISCUSSION
Data from the Modena HIV Metabolic Clinic cohort study show that HIV-infected people are
getting older, exhibiting an increased risk for age-associated chronic diseases compared to indi-
viduals of the same age sampled from the general population. In particular, this study identified
Table 1. Characteristics of HIV-Aging and HIV-Aged groups.
HIV-Aging HIV-Aged p-value
Sample size, n (%) 404 404 —
Men, n (%) 287 (71) 287 (71) 1
Age, mean ± S.D. 47 ± 6 47 ± 6 1
Current smoke, n (%) 0.017
None 192 (49) 207 (60)
Moderate* 71 (18) 45 (13)
Intense * 122 (31) 93 (26)
Anthropometry
BMI (kg/m2) (± S.D.) 23 (± 4) 25 (± 5) <0.001
Waist circumference (cm) (± S.D.) 87 (±10) 89 (±12) 0.007
Lipodistrophy, n (%) <0.001
No lipodistrophy 46 (12) 83 (23.2)
Lipoatrophy 160 (41) 101 (28)
Fat accumulation 180 (46) 173 (48)
Cardiovascular and metabolic markers
Triglycerides (mmol/L) median (IQR) 150 [105–230] 146 [100–230] 0.83
Total Cholesterol (mmol/L) mean ± S.D. 183 ± 44 199 ± 50 <0.001
High Density Lipoprotein (mmol/L), mean ± S.D. 45 ± 14 45 ± 13 0.7
Low Density Lipoprotein (mmol/L), mean ± S.D. 106 ±35 119 ±35 <0.001
Fasting Glucose (mmol/L), median (IQR) 91 [85–101] 92 [86–100] 0.96
HOMA, median (IQR) 3.5 [2.1–5.2] 2.6 [1.5–4.2] 0.001
* Moderate smoking is <10 cigarettes per day; intense smoking is 10 cigarettes per day.
doi:10.1371/journal.pone.0118531.t001
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that people with longer duration of HIV infection had relatively higher rates of hypertension
and MM than people who seroconverted at older ages.
At any age the risk for individual NICM as well as MM was 5 fold higher in people aging
with a longer duration of HIV infection compared to people without HIV, while HIV-positive
individuals who seroconverted at an older age had an intermediate risk.
Our results should be interpreted with caution, in particular with regard to reproducibility
of our results in different HIV settings. It has been argued that the tertiary referral setting of
the MHMCmay concentrate patients with higher prevalence of NICM and MM, However as
previously demonstrated in a sensitivity analysis this is not the case when comparing the preva-
lence of these conditions in patients referred from other centres[11]. In Italy, people with HIV
have full free access not only to HAART but also to clinical care including diagnostic proce-
dures with no co-pay. This might result in a selection bias as screening activities are offered rel-
atively more frequently to patients with HIV than the general population which might result in
higher rates of incidentally identified asymptomatic disease. The information available in the
CINECA-ARNO administrative database limited further comparisons in rates of NICM diag-
noses, as not all major risk factor for NICM are collected and clinical assessments are not
Fig 1. Prevalence of NICM and MM of HIV-Aging, HIV-Aged and HIV-negative groups.
doi:10.1371/journal.pone.0118531.g001
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provided. Moreover, with regard to CKD, the number of clinical events were very limited and
BMDmeasurements were not available in CINECA cohort. Finally, the cross-sectional design
of our study cannot prove causality regarding the impact of HIV duration on NICM or MM
risk, nor we were able to collect biomarkers of systemic and tissue inflammation to argue a
pathogenic link between HIV-related factors and MM.
Investigations of disease in people aging with HIV have so far primarily been limited to
comparisons between older and young HIV-positive persons, or else between older adults with
and without HIV[1]. Studies like the present one which investigate differences among groups
of people aging with HIV can yield greater insights into relationships between age, HIV dura-
tion, and health, and help identify which patients might be more vulnerable, in whom more
preventive interventions could be directed.
As universal access to HIV treatment and care continue to expand, the population of older
people with HIV will keep growing. A particular concern in this population regards MM as a
predictor care complexity and polypharmacy increasing the cost of clinical management[17].
Moreover polifarmacy rises risks of pharmacological interactions and medical errors[18–20].
Ageing and chronic HIV infection can also both contribute to subclinical changes, including
atherosclerosis, bone mineral density, and changes in T cell function.
Very few studies examined the impact of clinical intervention on both physical and neuro-
cognitive impairment associated with aging[21–25].
Fig 2. Probability for MM in the three comparative groups across age distribution.
doi:10.1371/journal.pone.0118531.g002
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Our results help reinforce the idea that as a group, people aging with HIV remain heteroge-
neous in terms of health. Factors such as longer duration of HIV treatment might be used in
clinical practice to inform clinical surveillance of disease risk, suggests frequency of follow-up,
intensity of care and treatment.
In conclusion, we identified that older HIV-positive adults exhibit higher rates of age-asso-
ciated chronic conditions and MM than HIV-negative individuals of the same age, further, that
people with longer duration of HIV infection show the higher probability of MM than people
who seroconverted at older ages.
We recommend that future longitudinal studies on older age and HIV reflect holistic views
of health, investigate the diversity of people aging with HIV, and take particular consideration
of the more vulnerable subset of people aging with longer duration of HIV infection.
Fig 3. Multivariable logistic regression model to detect independent predictors of MM in the HIV sample.
doi:10.1371/journal.pone.0118531.g003
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